Haemonetics Co. (NYSE:HAE) Insider Stewart W. Strong Sells 686 Shares

Haemonetics Co. (NYSE:HAE) insider Stewart W. Strong sold 686 shares of the stock in a transaction dated Monday, May 20th. The stock was sold at an average price of $95.11, for a total transaction of $65,245.46. Following the transaction, the insider now owns 18,196 shares in the company, valued at $1,730,621.56. The sale was disclosed in a filing with the SEC, which is available through this link.

Haemonetics Stock Down 2.2 %

NYSE:HAE opened at $93.20 on Wednesday. Haemonetics Co. has a fifty-two week low of $70.74 and a fifty-two week high of $97.97. The stock has a market capitalization of $4.73 billion, a P/E ratio of 40.70, a P/E/G ratio of 1.73 and a beta of 0.34. The company has a debt-to-equity ratio of 0.83, a quick ratio of 1.50 and a current ratio of 2.56. The company’s 50-day simple moving average is $86.98 and its 200-day simple moving average is $83.38.

Haemonetics (NYSE:HAE) last released its quarterly earnings results on Thursday, May 9th. The medical instruments supplier reported $0.90 earnings per share for the quarter, beating analysts’ consensus estimates of $0.88 by $0.02. Haemonetics had a net margin of 8.98% and a return on equity of 22.25%. The business had revenue of $343.00 million for the quarter, compared to analysts’ expectations of $329.53 million. During the same period last year, the business earned $0.77 EPS. The company’s revenue was up 12.7% compared to the same quarter last year. On average, equities analysts anticipate that Haemonetics Co. will post 4.6 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

HAE has been the topic of several recent research reports. Needham & Company LLC reiterated a “hold” rating on shares of Haemonetics in a report on Friday, May 10th. StockNews.com cut shares of Haemonetics from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. TheStreet cut shares of Haemonetics from a “b-” rating to a “c+” rating in a report on Thursday, February 29th. JMP Securities increased their target price on shares of Haemonetics from $115.00 to $125.00 and gave the stock a “market outperform” rating in a report on Friday, May 10th. Finally, Barrington Research raised their price target on shares of Haemonetics from $105.00 to $107.00 and gave the company an “outperform” rating in a report on Friday, May 10th. Three equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $108.67.

Hedge Funds Weigh In On Haemonetics

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Capital Research Global Investors raised its position in shares of Haemonetics by 2.3% in the 1st quarter. Capital Research Global Investors now owns 6,674,751 shares of the medical instruments supplier’s stock valued at $569,690,000 after purchasing an additional 151,183 shares during the last quarter. Vanguard Group Inc. raised its position in shares of Haemonetics by 0.5% in the 4th quarter. Vanguard Group Inc. now owns 5,406,309 shares of the medical instruments supplier’s stock valued at $462,293,000 after purchasing an additional 25,451 shares during the last quarter. Wellington Management Group LLP raised its position in shares of Haemonetics by 3.2% in the 4th quarter. Wellington Management Group LLP now owns 3,268,083 shares of the medical instruments supplier’s stock valued at $279,454,000 after purchasing an additional 101,029 shares during the last quarter. Dimensional Fund Advisors LP raised its position in shares of Haemonetics by 7.8% in the 4th quarter. Dimensional Fund Advisors LP now owns 826,731 shares of the medical instruments supplier’s stock valued at $70,697,000 after purchasing an additional 59,670 shares during the last quarter. Finally, Westfield Capital Management Co. LP raised its position in shares of Haemonetics by 27.2% in the 4th quarter. Westfield Capital Management Co. LP now owns 712,061 shares of the medical instruments supplier’s stock valued at $60,888,000 after purchasing an additional 152,098 shares during the last quarter. 99.67% of the stock is owned by hedge funds and other institutional investors.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system, and Donor360.